Successful completion of Institutional Entitlement Offer
Filed with ASX · · 2 pages · English
Chimeric Therapeutics Limited (ASX:CHM) (ChimericorCompany) refers to its announcement of 21 February 2022 in relation to an equity raising being undertaken by the Company by way of an accelerated 1 for 3.15 non-renounceable entitlement offer to raise approximately $18.1 million (before costs of the offer) (Entitlement Offer). The Entitlement Offer includes an institutional component (Institutiona
Chimeric Therapeutics Limited on 6ix
In the deck
Earlier from Chimeric Therapeutics
- Entitlement Offer to raise approximately $18.1 million
- Encouraging data from 2nd dose cohort in CLTX CAR T trial
- Sponsored Research Agreement with University of Pennsylvania
- Chimeric receives US patent covering CLTX CAR technology
- Transformative Portfolio Expansion Presentation
Later from Chimeric Therapeutics
- Chimeric partners with Be the Match BioTherapies
- Final Results in Phase 1 Trial of CORE NK Platform
- Security Class Suspension from Quotation CHMO
- Completion of retail component of Entitlement Offer
- CDH17 CAR t preclinical data featured in Nature Cancer
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics